日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma

ABBV-368、tilsotolimod、budigalimab 和 nab-paclitaxel 联合治疗复发/转移性头颈部鳞状细胞癌患者的 1b 期研究

期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2025-014086
Daste, Amaury; Le, Xiuning; Makkouk, Amani; Patel, Maulik; Le Tourneau, Christophe; Perets, Ruth; Popovtzer, Aron; Ochsenreither, Sebastian; Haderlein, Marlen; Oliva, Marc; Sukari, Ammar; Hong, Jaehyung; Blaney, Martha; Ramathal, Cyril; McDevitt, Michael; Rosenberg, Ari J
细胞生物学
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

一项评估simlukafusp alfa (FAP-IL2v)联合atezolizumab治疗复发性和/或转移性宫颈鳞状细胞癌患者的抗肿瘤活性和安全性的II期研究

期刊:EBioMedicine
影响因子:10.8
doi:10.1016/j.ebiom.2024.105374
Verlingue, Loic; Italiano, Antoine; Prenen, Hans; Guerra Alia, Eva Maria; Tosi, Diego; Perets, Ruth; Lugowska, Iwona; Moiseyenko, Vladimir; Gumus, Mahmut; Arslan, Cagatay; Lindsay, Colin R; Deva, Sanjeev; Taus, Álvaro; Oaknin, Ana; Rottey, Sylvie; Cicin, Irfan; Goksu, Sema Sezgin; Smolin, Alexey; Roselló-Keränen, Susana; Habigt, Christin; Marbach, Daniel; Boetsch, Christophe; Dejardin, David; Sleiman, Nassim; Evers, Stefan; Richard, Muriel; Ardeshir, Caroline; Charo, Jehad; Kraxner, Anton; Teichgräber, Volker; Keshelava, Nino; Dziadziuszko, Rafal
肿瘤
IL2
肿瘤免疫
FAP
细胞生物学
发表日期：2024
文献求助 收藏

The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies

KEYVIBE项目：维博斯托利单抗和帕博利珠单抗治疗晚期恶性肿瘤

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2024.2343272
Shapira-Frommer, Ronnie; Niu, Jiaxin; Perets, Ruth; Peters, Solange; Shouse, Geoffrey; Lugowska, Iwona; Garassino, Marina C; Sands, Jacob; Keenan, Tanya; Zhao, Bin; Healy, Jane; Ahn, Myung-Ju
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy

FRACTION-RCC：纳武利尤单抗联合伊匹木单抗治疗免疫肿瘤疗法进展后的晚期肾细胞癌

期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2022-005780
Choueiri, Toni K; Kluger, Harriet; George, Saby; Tykodi, Scott S; Kuzel, Timothy M; Perets, Ruth; Nair, Suresh; Procopio, Giuseppe; Carducci, Michael A; Castonguay, Vincent; Folefac, Edmund; Lee, Chung-Han; Hotte, Sebastien J; Miller, Wilson H Jr; Saggi, Shruti Shally; Lee, Chung-Wei; Desilva, Heshani; Bhagavatheeswaran, Prabhu; Motzer, Robert J; Escudier, Bernard
肿瘤
肿瘤免疫
肾癌
细胞生物学
免疫/内分泌
发表日期：2022
文献求助 收藏

First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

首个抗免疫球蛋白样转录物4髓系特异性抗体MK-4830可消除晚期实体瘤患者的PD-1耐药机制

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-21-2160
Siu, Lillian L; Wang, Ding; Hilton, John; Geva, Ravit; Rasco, Drew; Perets, Ruth; Abraham, Anson K; Wilson, Douglas C; Markensohn, Julia F; Lunceford, Jared; Suttner, Leah; Siddiqi, Shabana; Altura, Rachel A; Maurice-Dror, Corinne
PD-1
免疫/内分泌
发表日期：2022
文献求助 收藏

Correction: First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

更正：首创的抗免疫球蛋白样转录物4髓系特异性抗体MK-4830可消除晚期实体瘤患者的PD-1耐药机制

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-22-2320
Siu, Lillian L; Wang, Ding; Hilton, John; Geva, Ravit; Rasco, Drew; Perets, Ruth; Abraham, Anson K; Wilson, Douglas C; Markensohn, Julia F; Lunceford, Jared; Suttner, Leah; Siddiqi, Shabana; Altura, Rachel A; Maurice-Dror, Corinne
PD-1
免疫/内分泌
发表日期：2022
文献求助 收藏

PAX8 in the Junction between Development and Tumorigenesis

PAX8 在发育与肿瘤发生之间的交汇点

期刊:International Journal of Molecular Sciences
影响因子:4.9
doi:10.3390/ijms23137410
Kakun, Reli Rachel; Melamed, Zohar; Perets, Ruth
PAX8
发育与干细胞
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study

镭-223联合紫杉醇治疗骨转移癌患者：一项开放标签、多中心Ib期研究的安全性结果

期刊:European Journal of Nuclear Medicine and Molecular Imaging
影响因子:7.6
doi:10.1007/s00259-018-4234-6
Geva, Ravit; Lopez, Juanita; Danson, Sarah; Joensuu, Heikki; Peer, Avivit; Harris, Samuel J; Souza, Fabricio; Pereira, Kaline M C; Perets, Ruth
肿瘤
肿瘤免疫
发表日期：2019
文献求助 收藏

Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring

突变型KRAS循环肿瘤DNA是监测胰腺癌的准确工具

期刊:Oncologist
影响因子:4.2
doi:10.1634/theoncologist.2017-0467
Perets, Ruth; Greenberg, Orli; Shentzer, Talia; Semenisty, Valeria; Epelbaum, Ron; Bick, Tova; Sarji, Shada; Ben-Izhak, Ofer; Sabo, Edmond; Hershkovitz, Dov
胰腺癌
肿瘤
RAS
肿瘤免疫
发表日期：2018
文献求助 收藏

Genome-wide analysis of androgen receptor targets reveals COUP-TF1 as a novel player in human prostate cancer.

对雄激素受体靶点的全基因组分析揭示了 COUP-TF1 是人类前列腺癌中的一个新角色

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0046467
Perets Ruth, Kaplan Tommy, Stein Ilan, Hidas Guy, Tayeb Shay, Avraham Eti, Ben-Neriah Yinon, Simon Itamar, Pikarsky Eli
肿瘤
前列腺癌
Human
发表日期：2012
文献求助 收藏